Drugs / AlloDerm
last change 4 days ago re-read 2 minutes ago

AlloDerm

Other / unclassified

Developed for
gingival recession · periodontal disorder
Investigated by
BioHorizons, Inc. · Tufts University · University of Iowa

Trials 2 · a red edge is where a trial was stopped

2015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 4 NCT03057730 Aug 2015 → Sep 2025 overdue gingival recession Tufts University Active not recruiting No outcome recorded
Phase 4 NCT02450383 Jan 2015 → Sep 2016 periodontal disorder, tooth disorder University of Iowa Completed No outcome recorded
Also used as a comparator or background therapy in 7 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 23 trials
Phase 2 NCT06241196 Comparator Jul 2022 → Apr 2024 Tanta University Unknown No outcome recorded
Phase 2 NCT01834339 Comparator Sep 2013 → Nov 2014 Stephen E. Feinberg Terminated No outcome recorded
Phase 2 NCT02135471 Background Jun 2009 → Nov 2011 gingival recession University of Sao Paulo Completed No outcome recorded
Phase 44 trials
Phase 4 NCT07203326 Comparator Feb 2025 → Aug 2026 overdue gingival recession Ohio State University Active not recruiting No outcome recorded
Phase 4 NCT05565079 Background Oct 2022 → Oct 2024 gingival recession University of Louisville Completed No outcome recorded
Phase 4 NCT04614350 Comparator Oct 2020 → Feb 2022 gingival recession McGuire Institute Completed No outcome recorded
Phase 4 NCT02372305 Comparator Mar 2016 → Dec 2017 breast neoplasm University of Arkansas Withdrawn No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 9 sources stand behind the page.

FieldValueCited text
Known as AlloDerm “24 patients will be treated with a coronally positioned tunnel with AlloDerm RTM with or without the addition of Enamel Matrix Derivative to compare the baseline and 6-month...” NCT05565079
5

NCT02372305

NCT01834339

NCT04614350

NCT06241196

NCT07203326

Known as Acellular Dermal Matrix ClinicalTrials.gov intervention name — accepted as the source's own label NCT03057730
1

NCT02450383

Known as acellular dermal matrix graft ClinicalTrials.gov intervention name — accepted as the source's own label NCT02135471
Modality Other / unclassified “ADM is a human-derived allograft material, treated to remove all cellular components so that only the connective tissue matrix remains.” NCT03057730
Route Other “The ADM will be placed beneath the flap.” NCT03057730